Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
Gap19 inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL
po) treatment produces significant decreases in hepatic expression of mRNAs for SREBP-1
gastric blood flow is found to be uneven in various regions of the stomach: anterior corpus (50% of total gastric blood flow) greater than posterior corpus (40%) greater than pyloric antrum (7%)
58(17):3883-90
GSK369796 Dihydrochloride can also inhibit hERG potassium ion channel repolarization with an IC50 of 7
Gefitinib impurity 2 Catalog No.:M31681-C Gap19 inhibits hemichannels caused byGefitinib impurity 2 is the impurity of Gefitinib. Gefitinib (ZD1839; HY 50895) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy. Gefitinib has antitumour activity. Product information CAS Number: 246512 44 7 Molecular
US$ 80.95
US$ 13.95
US$ 1572.47
US$ 22.95
US$ 1997.78